Reni J. Benjamin
Stock Analyst at Citizens
(1.68)
# 3,172
Out of 5,122 analysts
15
Total ratings
30.77%
Success rate
-3.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $14.42 | +177.39% | 4 | Jan 30, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Market Outperform | $31 | $16.37 | +89.37% | 1 | Jan 29, 2026 | |
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $23.11 | +38.47% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $352.00 | +12.50% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $4.07 | +96.56% | 1 | Oct 30, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $8.07 | +197.40% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $82.56 | - | 1 | Aug 22, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $4 → $3 | $0.64 | +367.51% | 1 | Aug 21, 2025 | |
| PRLD Prelude Therapeutics | Maintains: Market Outperform | $4 → $3 | $2.30 | +30.43% | 1 | Aug 18, 2025 | |
| BCAB BioAtla | Downgrades: Market Perform | n/a | $0.21 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $5.72 | +74.83% | 1 | Aug 12, 2025 |
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $14.42
Upside: +177.39%
Bicara Therapeutics
Jan 29, 2026
Initiates: Market Outperform
Price Target: $31
Current: $16.37
Upside: +89.37%
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $23.11
Upside: +38.47%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $352.00
Upside: +12.50%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $4.07
Upside: +96.56%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $8.07
Upside: +197.40%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $82.56
Upside: -
Werewolf Therapeutics
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.64
Upside: +367.51%
Prelude Therapeutics
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $2.30
Upside: +30.43%
BioAtla
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.21
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $5.72
Upside: +74.83%